Market overview
The global molecular diagnostics market is worth USD 32.4 bn in 2026 and is forecast to reach USD 69.9 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and PCR and amplification is the largest by technology segment.
| Scope | Tests that detect DNA or RNA to diagnose disease, including PCR, isothermal amplification, in situ hybridization, microarray and sequencing-based clinical tests for infection, cancer and inherited conditions. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 30.0 bn |
| Value 2026 | USD 32.4 bn |
| Value 2036 | USD 69.9 bn |
| CAGR 2026-2036 | 8.0% |
| Volume 2026 | 2,149 million tests |
| Volume 2036 | 4,414 million tests |
| Average price 2026 | USD 15.1 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Molecular Diagnostics market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 32.4 bn |
| 2027 | USD 35.0 bn |
| 2028 | USD 37.8 bn |
| 2029 | USD 40.8 bn |
| 2030 | USD 44.1 bn |
| 2031 | USD 47.6 bn |
| 2032 | USD 51.4 bn |
| 2033 | USD 55.5 bn |
| 2034 | USD 60.0 bn |
| 2035 | USD 64.8 bn |
| 2036 | USD 69.9 bn |
Molecular Diagnostics market segmentation
By technology
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| PCR and amplification | 52.0% | 44.2% | USD 16.8 bn | 6.3% |
| Sequencing-based tests | 20.0% | 30.8% | USD 6.5 bn | 12.8% |
| In situ hybridization and microarrays | 10.0% | 7.4% | USD 3.2 bn | 4.8% |
| Other nucleic acid methods | 18.0% | 17.6% | USD 5.8 bn | 7.8% |
By application
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Infectious disease | 40.0% | 31.3% | USD 13.0 bn | 5.4% |
| Oncology | 25.0% | 32.6% | USD 8.1 bn | 10.9% |
| Genetic and prenatal | 15.0% | 16.3% | USD 4.9 bn | 8.9% |
| Transplant and other | 20.0% | 19.8% | USD 6.5 bn | 7.9% |
By product
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Reagents and kits | 56.0% | 52.0% | USD 18.1 bn | 7.2% |
| Instruments | 28.0% | 29.0% | USD 9.1 bn | 8.4% |
| Software and services | 16.0% | 19.0% | USD 5.2 bn | 9.9% |
By test setting
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Central laboratory | 54.0% | 48.0% | USD 17.5 bn | 6.7% |
| Point-of-care | 22.0% | 28.0% | USD 7.1 bn | 10.6% |
| Home and decentralized | 10.0% | 11.0% | USD 3.2 bn | 9.0% |
| Hospital laboratory | 14.0% | 13.0% | USD 4.5 bn | 7.2% |
By pathogen or target
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Infectious disease | 38.0% | 34.0% | USD 12.3 bn | 6.8% |
| Oncology biomarkers | 28.0% | 32.0% | USD 9.1 bn | 9.4% |
| Genetic disorders | 18.0% | 19.0% | USD 5.8 bn | 8.6% |
| Cardiometabolic and other | 16.0% | 15.0% | USD 5.2 bn | 7.3% |
Top 25 countries for molecular diagnostics by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 83.5% of 2026 revenue and the 25 countries below together hold 96.0%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 13.0 bn | 40.0% | USD 26.5 bn | 7.4% |
| 2 | China | USD 3.9 bn | 12.0% | USD 10.0 bn | 9.9% |
| 3 | Germany | USD 2.3 bn | 7.0% | USD 4.6 bn | 7.4% |
| 4 | Japan | USD 1.6 bn | 5.0% | USD 3.0 bn | 6.4% |
| 5 | France | USD 1.3 bn | 4.0% | USD 2.7 bn | 7.5% |
| 6 | United Kingdom | USD 1.3 bn | 4.0% | USD 2.8 bn | 8.0% |
| 7 | Italy | USD 972 mn | 3.0% | USD 2.0 bn | 7.3% |
| 8 | India | USD 972 mn | 3.0% | USD 3.0 bn | 12.0% |
| 9 | Spain | USD 972 mn | 3.0% | USD 2.1 bn | 8.0% |
| 10 | Brazil | USD 810 mn | 2.5% | USD 1.9 bn | 8.8% |
| 11 | South Korea | USD 629 mn | 1.9% | USD 1.4 bn | 7.9% |
| 12 | Canada | USD 577 mn | 1.8% | USD 1.2 bn | 7.9% |
| 13 | Australia | USD 509 mn | 1.6% | USD 1.1 bn | 7.9% |
| 14 | Netherlands | USD 402 mn | 1.2% | USD 860 mn | 7.9% |
| 15 | Mexico | USD 327 mn | 1.0% | USD 706 mn | 8.0% |
| 16 | Russia | USD 301 mn | 0.9% | USD 644 mn | 7.9% |
| 17 | Switzerland | USD 266 mn | 0.8% | USD 574 mn | 8.0% |
| 18 | Turkey | USD 211 mn | 0.7% | USD 448 mn | 7.8% |
| 19 | Poland | USD 185 mn | 0.6% | USD 399 mn | 8.0% |
| 20 | Belgium | USD 162 mn | 0.5% | USD 350 mn | 8.0% |
| 21 | Sweden | USD 139 mn | 0.4% | USD 301 mn | 8.0% |
| 22 | Taiwan | USD 110 mn | 0.3% | USD 238 mn | 8.0% |
| 23 | Singapore | USD 91 mn | 0.3% | USD 189 mn | 7.6% |
| 24 | Thailand | USD 81 mn | 0.2% | USD 175 mn | 8.0% |
| 25 | Saudi Arabia | USD 71 mn | 0.2% | USD 154 mn | 8.0% |
| Rest of world | USD 1.3 bn | 4.0% | USD 2.7 bn | 7.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Roche
- Abbott
- Danaher (Cepheid)
- Hologic
- Thermo Fisher Scientific
- QIAGEN
Group 2: Regional and specialist players
- bioMerieux
- Becton Dickinson
- Illumina
- Bio-Rad Laboratories
- Siemens Healthineers
- Exact Sciences
- Seegene
- DiaSorin
- Sysmex
- Agilent Technologies
Group 3: Emerging and niche players
- Natera
- Guardant Health
- Sansure Biotech
- Daan Gene
- Biocartis
- Co-Diagnostics
- Visby Medical
- Bioneer
- Veracyte
- Burning Rock Biotech
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the molecular diagnostics market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.
The market is divided by technology, by application, by product, by test setting, by pathogen or target. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the molecular diagnostics market?
The global molecular diagnostics market is estimated at USD 30.0 bn in 2025 and USD 32.4 bn in 2026.
How fast will the molecular diagnostics market grow?
It is forecast to reach USD 69.9 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 37.5 bn.
Which country is the largest market for molecular diagnostics?
United States is the largest market by revenue at USD 13.0 bn in 2026, 40.0% of the global total. The three largest countries together hold 59.0%.
Which country is growing fastest?
Among the ten largest markets, India is growing fastest at 12.0% a year from 2026 to 2036.
Which molecular diagnostics segment is largest?
In the by technology split, PCR and amplification is the largest segment with 52.0% of 2026 revenue.
Who are the leading molecular diagnostics companies?
Global leaders include Roche, Abbott, Danaher (Cepheid), Hologic.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Diabetes CareUSD 32.7 bn · 9.0% CAGR
- Regenerative MedicineUSD 31.6 bn · 13.0% CAGR
- Obesity DrugsUSD 33.3 bn · 14.0% CAGR
- Nasal SprayUSD 35.0 bn · 5.5% CAGR
- Clinical NutritionUSD 35.3 bn · 7.0% CAGR
- Ocular Drug DeliveryUSD 29.7 bn · 6.0% CAGR
- BiosimilarsUSD 37.8 bn · 15.0% CAGR
- Wound CareUSD 26.5 bn · 6.0% CAGR
← Mixed Reality Navigation Platforms Monoclonal Antibodies →